New clinical and real-world evidence on Lecanemab to be presented at AAIC conference 2026

BioArctic AB’s partner Eisai will present new clinical and real-world evidence on lecanemab (Leqembi) at the Alzheimer’s Association International Conference (AAIC) in London July 12-15. While specific efficacy/safety figures weren’t provided in the article excerpt, the planned disclosure of additional data is a modest positive catalyst for sentiment around the therapy.

Analysis

BioArctic AB’s partner Eisai will present new clinical and real-world evidence on lecanemab (Leqembi) at the Alzheimer’s Association International Conference (AAIC) in London July 12-15. While specific efficacy/safety figures weren’t provided in the article excerpt, the planned disclosure of additional data is a modest positive catalyst for sentiment around the therapy.